Skye Bioscience (FRA:09R) Minority Interest: €0.00 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:09R Skye Bioscience Inc FRA:09R
19 GF Score
Price €0.53
! 1 Warning Sign
View Full Analysis

What is Skye Bioscience Minority Interest?

Skye Bioscience FRA:09R -3.64% 19 Minority Interest is €0.00 Mil as of Mar. 2026. GuruFocus rates FRA:09R with a GF Score™ of 19/100. The stock has 1 warning sign investors should review.

Minority interest is the carrying amount of the equity interests owned by non-controlling shareholders, partners, or other equity holders in one or more of the entities included in the reporting entity's consolidated financial statements.

Skye Bioscience's minority interest for the quarter that ended in Mar. 2026 was €0.00 Mil.

Skye Bioscience Minority Interest Historical Data

* Premium members only.

The historical data trend for Skye Bioscience's Minority Interest can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Skye Bioscience Minority Interest Chart

Skye Bioscience Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Minority Interest
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Skye Bioscience Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Minority Interest Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
FRA:09R
19GF Score
Skye Bioscience Inc FRA:09R
Minority Interest is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Skye Bioscience Minority Interest Calculation

Minority interest is the carrying amount of the equity interests owned by non-controlling shareholders, partners, or other equity holders in one or more of the entities included in the reporting entity's consolidated financial statements.

Frequently Asked Questions Learn more about Minority Interest →
What does a Minority Interest of €0.00 Mil mean?
Skye Bioscience (FRA:09R) has a Minority Interest of €0.00 Mil as of Mar. 2026. Minority interest represents the carrying value of equity from non-controlling shareholders and company partners. View historical data on Skye Bioscience.
Is Skye Bioscience's Minority Interest too high?
Skye Bioscience's current Minority Interest is €0.00 Mil. Overall, Skye Bioscience has a GF Score™ of 19/100, reflecting its overall financial health beyond just this single metric.
How does Skye Bioscience's Minority Interest compare to ATOS and JSPR?
Skye Bioscience's Minority Interest of €0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Minority Interest for a Biotechnology company?
A good Minority Interest depends on the Biotechnology industry context. However, Minority Interest should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Minority Interest mean?
A high Minority Interest can signal that a stock is expensive relative to its fundamentals. Minority interest represents the carrying value of equity from non-controlling shareholders and company partners. View historical data on Skye Bioscience. Skye Bioscience's current Minority Interest is €0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Skye Bioscience stock overvalued right now?
Skye Bioscience (FRA:09R) has a current Minority Interest of €0.00 Mil. The current Minority Interest is €0.00 Mil. Skye Bioscience's overall GF Score™ is 19/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Minority Interest calculated?
Minority Interest is calculated from a company's financial statements. For Skye Bioscience (FRA:09R), the current Minority Interest is €0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Skye Bioscience Business Description

Other Exchanges SKYE:USA
Address 11250 El Camino Real, Suite 100, San Diego, CA, USA, 92130
Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis, and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.
19GF Score

Get the complete analysis for FRA:09R

Minority Interest is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.53
Price